In relation to the establishment, Ariana has appointed James Shanahan as VP of business development. James was previously a co-founder and is current board member of SynDevRx.
Ariana president and CEO Mohammad Afshar said, "Our KEM technology is the only proven approach that can simultaneously analyze all these variables and pull out patient responder sub-groups, optimize biomarker signatures and remove bias from clinical trials."
Ariana’s Knowledge Extraction and Management (KEM) is an association rules-based (non-statistical) analytical technology that finds patient responder sub-populations and biomarker signatures that statistical methods are unable to detect.
KEM lowers the number of patients needed to reach clinical endpoints by optimizing clinical trial inclusion/exclusion criteria, the company said.